This trial is evaluating whether ACTHAR Gel (adrenocorticotropic hormone) will improve 1 primary outcome and 9 secondary outcomes in patients with Hypercalcemia Due to Sarcoidosis. Measurement will happen over the course of Baseline compared to 12 weeks..
This trial requires 10 total participants across 2 different treatment groups
This trial involves 2 different treatments. ACTHAR Gel (adrenocorticotropic Hormone) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.